Comparative Pharmacology
Head-to-head clinical analysis: NEXAVAR versus PONLIMSI.
Peer-Reviewed Evidence
Head-to-head clinical analysis: NEXAVAR versus PONLIMSI.
NEXAVAR vs PONLIMSI
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Multikinase inhibitor targeting Raf, VEGFR-2, VEGFR-3, PDGFR-β, c-KIT, Flt-3, and RET kinases, inhibiting tumor growth and angiogenesis.
Ponlimsi is a small molecule inhibitor of the bromodomain and extraterminal (BET) family of proteins, specifically BRD2, BRD3, BRD4, and BRDT. It binds to acetyl-lysine recognition motifs, displacing BET proteins from chromatin, thereby inhibiting transcription of oncogenes such as MYC and BCL2.
400 mg (two 200 mg tablets) orally twice daily approximately 12 hours apart on an empty stomach (at least 1 hour before or 2 hours after a meal).
100 mg IV over 30 minutes on Days 1, 8, and 15 of a 28-day cycle.
None Documented
None Documented
Terminal half-life 25-48 hours; supports twice-daily dosing with steady state achieved in 7-14 days.
Terminal half-life is 24 hours (range 20-28 h), supporting once-daily dosing.
Fecal (77% as unchanged drug and metabolites), renal (19% as metabolites, <1% as unchanged drug).
Primarily renal (60% unchanged) and biliary (30% as metabolites), with 10% fecal.
Category C
Category C
Tyrosine Kinase Inhibitor
Tyrosine Kinase Inhibitor